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Abstract Pregnancy in chronic dialysis patients is
unusual and associated with many complications.
Infants are often born both prematurely and small for
gestational age. We report a case of a 36-year-old
diabetic hemodialysis patient G4P3 who had pro-
longed hyperemesis gravidarum, for whom intradia-
lytic parenteral nutrition (IDPN) was started at week
14 and continued throughout her pregnancy. She
delivered a 3.5-kg baby girl at the 36th week of
gestation by cesarean section. We discuss the use of
IDPN as adjunct therapy for pregnant dialysis
patients.
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Introduction
Pregnancy is rare among childbearing women with
end-stage renal disease (ESRD) on renal replacement
therapy. Rate of conception in dialysis patients has
ranged from 0.9% in 1980 to 2.4% in 1998 [1, 2].
While still uncommon, the incidence of pregnancy in
women with ESRD seems to be increasing. However,
the few successful pregnancies are often associated
with a wide range of complications, including
spontaneous abortion, preterm birth, intrauterine
growth restriction, polyhydramnios and fetal demise
[3]. Advances in dialysis technology, obstetrical
monitoring, and neonatal intensive care over the last
twenty years have dramatically improved fetal sur-
vival rates to roughly 80% [1], yet the mean
gestational age at delivery is still 32 weeks, and
preterm birth is seen in 80% of pregnancies in
dialysis-dependent women [4].
Indeed, these pregnancies are challenging both for
the patients and their providers. Intensive dialysis
regimens are believed to reduce the fetal uremic
environment, minimize large ﬂuid shifts and placental
hypoperfusion and allow greater dietary freedom with
nutritional beneﬁts [5, 6]. Trends toward improved
fetal and maternal outcomes have been noted with
increased dialysis delivery [7, 8], and a negative
correlation between gestational age and birth weight
and maternal blood urea nitrogen level has been
observed [9]. Intensive hemodiaﬁltration has also
been associated with improved fetal outcomes [3].
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sive dialysis with 35–56 h/week of therapy, has been
associated with higher fertility rates among women, as
well as improved fetal outcomes, compared to previ-
ous reports [10]. While there has never been a direct
comparison of standard and intensive dialysis regi-
mens in pregnant women, 20 h/week of dialysis seems
to be the minimum recommended dose to improve
fetal outcomes [1]. This requires signiﬁcant commit-
ment from the patient, dialysis center and healthcare
team.
Adequate maternal nutrition is a backbone of good
prenatal care. The key components of a healthy diet
during pregnancy include increased protein intake of
approximately 1.2 g/kg, appropriate vitamin and
mineral supplementation, and consumption of a
variety of foods, all leading to an appropriate weight
gain of 11.5–16 kg per singleton pregnancy [11].
Maintaining adequate nutrition with renal failure is a
well-described challenge for patients with ESRD [12,
13]. Thus, pregnant women on dialysis face additional
difﬁculties achieving adequate nutrition. For example,
pregnant women on dialysis must ingest at least 1.8 g/
kg/day of protein to maintain a neutral nitrogen
balance [5] and increase their caloric intake by
300 kilocalories to prevent wasting [14]. The inten-
sive dialysis regimens of pregnancy lead to increased
losses of water-soluble vitamins in the dialysate, thus
requiring ample supplementation of folic acid, zinc
and renal-formulated multivitamins. In addition, the
calcium–phosphorus product must be monitored
closely to promote adequate fetal skeletal develop-
ment, while preventing complications associated with
metabolic bone disease [14]. Despite awareness
surrounding these increased needs, there is a paucity
of literature to help practitioners develop a dietary
protocol for their pregnant dialysis patients.
On this challenging backdrop, the presence of
hyperemesis gravidarum makes managing such
patients even more difﬁcult. Hyperemesis gravidarum
is a condition deﬁned by unexplainable, intractable
vomiting and dehydration, leading to [5% of pre-
pregnancy weight loss [15]. It affects 0.3–2% of
pregnant women and may require nutritional support
to maintain fetal and maternal health.
We describe a case of a pregnant woman with
ESRD and severe hyperemesis gravidarum who was
treated with intradialytic parenteral nutrition (IDPN)
for the last 22 weeks of her pregnancy. Details of her
nutritional status, dialysis regimen, and obstetric
management are included. In the discussion, we
review the role of IDPN in pregnancy, ESRD and
ﬁnally in neonatal outcomes in women with ESRD.
Case report
A 36-year-old woman, gravida four, para three, with
ESRD presumed secondary to diabetes in the absence
of a biopsy, initiated on hemodialysis eight months
prior, presented to the emergency room with one week
of intermittent abdominal pain, nausea and vomiting,
and was found to be 8 weeks pregnant by ultrasound
dates. Her past medical history included insulin-
dependent diabetes mellitus for 11 years associated
with mild proliferative retinopathy and hypertension
requiring multiple medications. Her surgical history
was signiﬁcant for three prior term cesarean sections.
Given the increased risk of maternal mortality and
fetal complications associated with pregnancy in
ESRD, she underwent intensive counseling and ulti-
mately elected to continue with the pregnancy. At that
point, her dialysis regimen was intensiﬁed to a
regimen consisting of 24 h/week (four hour treatment
sessions on six days per week). Dialysate composi-
tion consisted of potassium 4 mmol/L, bicarbonate
25 mmol/L, calcium 1.25 mmol/L and sodium
140 mmol/L. The dialysate was supplemented with
an IV infusion of potassium phosphate 30 mmol with
each dialysis run, on account of persistent hypophos-
phatemia from poor oral intake and intensive dialysis.
Dialysate ﬂow was 800 ml/min, and blood ﬂow was
400 ml/min via a left upper extremity AV ﬁstula. Her
mid-week standardized Kt/V was 1.42 (range 1.26–
1.59). She was anticoagulated with unfractionated
heparin. Her medications consisted of labetolol
100 mg twice per day, prenatal multivitamin one
tablet daily, folic acid 1 mg daily, vitamin B6 100 mg
daily, calcium carbonate 1,250 mg with meals, eryth-
ropoietin IV three times a week (TIW) to keep
hemoglobin levels between 10 and 11 g/L, IV iron
supplementation according the dialysis unit anemia
management protocol (total 1,200 mg in nine months)
and oral calcitriol 0.25 mg TIW.
Weeks after her pregnancy was discovered, she
continued to have abdominal pain and vomiting
requiring hospitalization; further workup of elevated
serum liver enzyme levels including an abnormal
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acute cholecystitis. Due to heightened surgical risks
associated with pregnant patients, initial management
of the acute disease was conservative, with bowel rest
and IV hydration. She continued suffering from
recurrent attacks of abdominal pain and vomiting,
withcontinualinabilitytomaintainappropriatecaloric
intake, and persistently elevated serum liver enzyme
levels. At 14 weeks of pregnancy, her estimated dry
weight (EDW) was 71.5 kg, a 5.5 kg loss compared to
her pre-pregnancy dry weight of 76 kg (155% IBW,
BMI = 31.1 kg/m
2) and her nutritional protein cata-
bolic rate (nPCR) was only 0.55. Intradialytic paren-
teral nutrition (IDPN) was thus initiated. Her
estimated nutrient requirements were 2,100–2,250 ki-
localories (kcal) [
1REE 9 1.2–1.3 ? 300 kcal for
pregnancy] and 75–85 g protein [
2MAW 9 1.4–1.5].
The IDPN provided 95 g of protein (15% amino acids,
380 kcal), 100 g dextrose (340 kcal) and 40 g of lipid
(400 kcal) for a total of 1.5 calories/ml and 1,120 kcal
per bag. She received one bag of IDPN at each dialysis
session. At 18 weeks of pregnancy, she underwent
laparoscopic cholecystectomy without complications
for persistently symptomatic cholecystitis.
After surgery, her liver enzymes normalized, yet
she continued to experience intractable nausea and
vomiting for two subsequent months without a clear
etiology. While she was unable to reliably complete
caloriecountquestionnaires,shewouldalwaysremark
on her inability to consume a normal meal and her
serum phosphorous levels declined even further than
expected for her intensive dialysis regimen. Further-
more, her weekly ultraﬁltration requirements
remained extremely low, averaging 1.1 L per week,
further conﬁrming her very poor PO intake. She was
thus diagnosed with severe hyperemesis gravidarum
and was unsuccessfully treated with anti-emetics. She
continued to have poor appetite and weight loss until
week 26 of her pregnancy, when her EDW stabilized
between 72 and 74 kg, rather than continuing its
downward trajectory.
For the remainder of her pregnancy, she was
maintained on IDPN, the frequency of emeses
decreased, and she started to eat more regularly. Her
EDW slowly increased, demonstrating true weight
gain, as she never developed any edema or other signs
of increased extracellular volume. While her albumin
never improved, her pre-albumin did increase with
time,upto33 mg/dLatweek29.Inaddition,hernPCR
rose,fromanadirof0.55atweek12ofpregnancyprior
to starting IDPN, to a height of 1.65 at week 20. For
comparison, her pre-pregnancy nPCR was 1.23.
Fetal monitoring occurred with frequent, serial
ultrasounds. Despite poor maternal nutrition, obstetric
ultrasounds at 17, 29 and 33 weeks of gestation
revealed normal fetal weight for gestational age.
Polyhydramnios was noted on ultrasound at week 33,
and given the ongoing risk of maternal and fetal
complications, including fetal demise; she was admit-
ted to the hospital for a cesarean delivery at 36 weeks
of gestation after undergoing an amniocentesis for
fetal lung maturity. The female neonate weighed
3,505 g, with Apgar scores of 7 and 9.
Discussion
Although parenteral nutrition has been used in
pregnant women with normal renal function and
in non-pregnant patients with renal failure, its use in
pregnantdialysis-dependentpatientshasbeenreported
onlyonce[16].Thelackofliteratureinpartreﬂectsthe
uncertainty and controversy associated with the use of
parenteral hyperalimentation.
In a recent prospective, randomized study of 200
malnourished hemodialysis patients, no signiﬁcant
advantages of IDPN in addition to a successful oral
supplementationprogramweredemonstrated,interms
of mortality or morbidity. Both the control and IDPN
groups, however, exhibited improvement in nutri-
tional status, as deﬁned by serum albumin, serum pre-
albumin and BMI [17]. This is important to note, as
increases in serum pre-albumin levels during nutri-
tional therapy wasassociated with decreased mortality
and hospitalization risk. This corroborated the results
of previous randomized studies that showed improve-
ment in body weight and nutritional parameters in
hemodialysis patients receiving some form of supple-
mentalnutrition,includingIDPNalone[18].IDPNhas
also been noted effective in ESRD patients with acute
medical or surgical illnesses causing states of hyper-
catabolism, such as sepsis, pancreatitis and inﬂamma-
tory states that develop after lower limb amputation
[19].
1 REE–Resting energy expenditure.
2 MAW–metabolically active weight.
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state of increased metabolic demand. Pregnant women
who suffer from severe hyperemesis gravidarum
cannot match their caloric and protein intake with
their increased needs; total parenteral nutrition (TPN)
has been used safely in such settings to ensure
adequate maternal nutrition and normal fetal growth
[15, 20]. However, TPN is associated with infectious
complications as well as those associated with central
catheter placement. Better pregnancy outcomes with
fewer infectious complications (UTI, pneumonia)
occur in women who need short-term TPN rather than
those women who require long-term hyperalimenta-
tion [20, 21]. Therefore, great care should be taken to
select appropriate pregnant patients for use of paren-
teral nutrition.
The case presented here describes a pregnant
woman with severely compromised oral intake and
weight loss due to cholecystitis and persistent hyper-
emesis gravidarum, superimposed on a malnourished
state associated with ESRD. Despite her complicated
clinical course, after initiation of IDPN, her weight
stabilized. Over time, the parenteral nutrition helped
improve her metabolic and nutritional parameters and
enabled her to regain most of the weight that she had
lost between weeks 9 and 14 of her pregnancy. Her
pre-albumin levels increased from 29 to 33, and her
weight at delivery was 85 kg, representing a 9 kg
weight gain from her non-pregnant weight.
Preterm infants born to dialysis patients are often
small for gestational age, as well as premature [4, 22].
Our patient carried her pregnancy to near term and
delivered a healthy female neonate, who was normal
in size and weight throughout the pregnancy, despite
the months of poor oral intake and weight loss.
While pregnant women with diabetes are known to
have large infants [23], the patient in this case had
normal blood sugars throughout her pregnancy and
HgA1C levels that ﬂuctuated between 4.3 and 5.1%
without medication. The baby’s normal birth weight
was thus less likely a product of maternal glucose
intolerance and more likely a reﬂection of adequate
maternal nutrition, largely achieved with IDPN. Iron
deﬁciency has also been associated with reduced fetal
growth [24]; this patient’s iron studies were always
within the normal range and monitored every three
months.
Though controversial, improvements in dialysis,
obstetrical care and antenatal fetal monitoring over
the past two decades appear to have increased fertility
rates and successful pregnancies in dialysis-depen-
dent women. Moving forward, more robust studies
are needed to further improve maternal and fetal
health and to develop guidelines for practitioners
caring for this complex patient population. This case
highlights the importance of nutritional supplemen-
tation in pregnant patients with ESRD and suggests
that IDPN may be associated with improvement or
normalization of fetal birth weights.
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